Bladder cancer drug developer BioClin Therapeutics, backed by Novo, has increased its latest funding round from $30m to $50m.
BioClin Therapeutics, a US-based cancer therapy developer that counts pharmaceutical company Novo as an investor, added $20m on Wednesday to a series B round now sized at $50m.
Sectoral Asset Management and Inkef Capital put up the extra cash. Sofinnova Ventures, Ysios Capital, HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP) had funded the $30m first tranche, which closed in March 2017.
BioClin is working on a monoclonal antibody that will treat metastatic bladder cancer, and the…